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Background: Philadelphia positive leukemias are characterized by the presence of Bcr-Abl fusion protein which
exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the
treatment of Ph (+) leukemias. Despite high rates of clinical response, Ph (+) patients can develop resistance against
these kinase inhibitors mainly due to point mutations within the Abl protein. Of special interest is the ‘gatekeeper’
T315I mutation, which confers complete resistance to Abl kinase inhibitors. Recently, GNF-2, Abl allosteric kinase
inhibitor, was demonstrated to possess cellular activity against Bcr-Abl transformed cells. Similarly to Abl kinase
inhibitors (AKIs), GNF-2 failed to inhibit activity of mutated Bcr-Abl carrying the T315I mutation.
Methods: Ba/F3 cells harboring native or T315I mutated Bcr-Abl constructs were treated with GNF-2 and AKIs. We
monitored the effect of GNF-2 with AKIs on the proliferation and clonigenicity of the different Ba/F3 cells. In
addition, we monitored the auto-phosphorylation activity of Bcr-Abl and JAK2 in cells treated with GNF-2 and AKIs.
Results: In this study, we report a cooperation between AKIs and GNF-2 in inhibiting proliferation and clonigenicity
of Ba/F3 cells carrying T315I mutated Bcr-Abl. Interestingly, cooperation was most evident between Dasatinib and
GNF-2. Furthermore, we showed that GNF-2 was moderately active in inhibiting the activity of JAK2 kinase, and
presence of AKIs augmented GNF-2 activity.
Conclusions: Our data illustrated the ability of allosteric inhibitors such as GNF-2 to cooperate with AKIs to
overcome T315I mutation by Bcr-Abl-independent mechanisms, providing a possibility of enhancing AKIs efficacy
and overcoming resistance in Ph+ leukemia cells.
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Philadelphia positive leukemias are hematological malig-
nancies caused by a chromosomal rearrangement that
generates a fusion protein, Bcr–Abl, with deregulated
tyrosine kinase activity. Imatinib, which targets the ATP-
binding site, is effective in the early stage of the treat-
ment of Ph-positive patients, but advanced-stage patients
may relapse as a result of the emergence of point* Correspondence: jamalm@migal.org.il
1Cancer Drug Discovery Program, Galilee Technology Center, Migal, P.O.Box
831, Kiryat Shmona 11016, Israel
4Department of Nutritional Sciences, Tel-Hai College, Kiryat Shmona, Israel
Full list of author information is available at the end of the article
© 2012 Khateb et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormutations within the Bcr–Abl. Two recently approved
drugs, Nilotinib [1] and Dasatinib [2] inhibit the activity
of mutated Bcr-Abl that is refractory to Imatinib except
the ‘gatekeeper’ T315I mutation, which is situated in the
middle of the ATP-binding cleft [3].
Allosteric kinase inhibitors hold promise for revealing
unique features of kinases that may not be apparent
using conventional ATP-competitive inhibitors. Thus,
using an unbiased cellular screening approach, GNF-2, a
non-ATP-competitive inhibitor, has been identified and
shown to demonstrate cellular activity against Bcr-Abl
transformed cells [4]. The exquisite selectivity of GNF-2
is due to the finding that it targets the myristate bindingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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main, as demonstrated by genetic approaches, solution
NMR, X-ray crystallography, mutagenesis and hydrogen
exchange mass spectrometry [5]. GNF-2, like myristate,
is able to induce and/or stabilize the clamped inactive
conformation of Abl, analogous to the SH2-Y527 inter-
action of Src [6]. Crystallography study revealed that
GNF-2 replaces the myristoylated peptide in the crystals
[5]. As expected, most of the interactions between GNF-
2 and the protein are hydrophobic. Mutations of three
residues near the mouth of the myristate-binding site
(C464Y, P465S and V506L) were reported to cause re-
sistance to the binding of GNF-2, presumably for steric
reasons. The myristate-binding-site mutant, E505K, was
inhibited by Imatinib and Nilotinib, but not by GNF-2,
arguing that GNF-2 targets the myristoyl pocket [5].
In this report we showed that GNF-2 cooperated with
the Abl kinase inhibitors (AKIs), Imatinib, Nilotinib and
Dasatinib, in inhibiting clonigenicity of Bcr-Abl T315I
transformed Ba/F3 cells. Interestingly, activity against
T315I mutation was Bcr-Abl independent. Furthermore,
GNF-2 and AKIs also cooperated to inhibit JAK2 phos-
phorylation in Ba/F3 carrying T315I mutation.
Materials and methods
Cell lines and cell cultures
Ba/F3 cells expressing Bcr-Abl constructs or activated
JAK2 (V617F) were previously described [7] and grown
in RPMI 1640 with 2 mM L-glutamine supplemented
with 10% fetal bovine serum. Penicillin at 100 U/ml, and
streptomycin at 100 μg/ml, was added to the culture
media. SupB15, a Ph+ ALL B cell (ATCC, Rockville, MD)
was grown in RPMI 1640 containing 2 mM L-glutamine,
20% FBS, 100 U/ml penicillin and 100 μg/ml strepto-
mycin. All cell lines were grown at 37°C in a humidified
atmosphere with 5% CO2.
Cellular Bcr-Abl auto-phosphorylation and
immune-blotting
Ba/F3 cells expressing the native or the T315I mutated
Bcr-Abl protein (4 x 105 cells/ml) were treated with Abl
kinase inhibitors (AKIs), GNF-2, combinations of GNF-2
and AKIs and DMSO for 1 h. Cells were collected,
washed once with cold PBS, and lysed as previously
describe [7]. Cell lysate supernatants (40 μg protein)
were resolved on 8% SDS-polyacrylamide gel electro-
phoresis, transferred to nitrocellulose membranes, and ana-
lyzed by immune-blotting with Anti-phospho-c-Abl
(Tyr245), Anti-phospho-STAT5α (Tyr694) and anti-
phospho JAK2 (Tyr1007/1008) antibodies (Cell Signaling
Technology, USA). The phosphorylated level of Bcr-Abl
protein was compared to total Abl or α-tubulin that were
detected using Anti-c-Abl and Anti-α-tubulin antibodies
(Santa Cruz Biotechnology, USA). Quantitative analysis ofthe protein bands detected by Western blot was carried out
using Tina software 2.0. Analyses of pSTATα pBcr-Abl and
pJAK2 levels are given as folds of the sample values versus
the α -tubulin values used as a loading control.
Trypan blue exclusion assay
Ba/F3 cells containing Bcr-Abl constructs were plated
(4x 105 cells/well) in six-well plates, with each well con-
taining 3 ml medium. After 24 h, cells were treated with
the appropriate agents. Solvent-treated samples were in-
cubated with 1% DMSO. Seventy-two hours later, the
cells were collected, stained with 0.4% trypan blue solu-
tion (1:1), and counted using a hemocytometer to deter-
mine IC50 values.
Colony-forming assay
A colony-forming assay was performed as previously
described [7]. Briefly, cells (1 x 104) in 1 ml RPMI/10%
FBS medium were diluted in 1 ml of 0.6% agar to give a
final agar concentration of 0.3% agar. The cell-agar mix-
ture was poured on top of a hardened agar base in wells of
12-well plates and allowed to solidify. Once the top layer
solidified, 1 ml of medium containing different treatments
was placed on top to keep the agar moist. The cells were
grown at 37°C in a 5% CO2 humidified atmosphere until
colonies were visible (2 weeks). The plates were stained
for 4 h with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), and the dye was
extracted with 1 ml solubilization buffer (20% sodium
dodecyl sulfate [SDS], 50% N,N-dimethyl-formamide,
25 mM HCL) for 24 h. The optical density was measured
at 570 nm wavelength with a reference wavelength of
630 nm.
Statistical analysis
Statistical analysis was performed using Student’s t-test,
with significant values set at *P<0.05 or **P<0.005.
Results
Since the efficacy of Imatinib and other ATP-competitors
are moderate in ALL patients, and based on our previous
work showing that the allosteric inhibitor GNF-2 is less
active on p185 Bcr-Abl [8]; we wanted to seek efficacy
improvement by combination of ATP-competitor with
allosteric inhibitors, such as GNF-2. Initially, we tested
the influence of suboptimal Imatinib (0.2 μM) and Dasa-
tinib (2 nM) concentrations on the anti-proliferative ac-
tivity of GNF-2 using Ba/F3 p185 Bcr-Abl transfected
cells. Imatinib (0.2 μM) and Dasatinib (2 nM) exhibited
only marginal effect on proliferation of Ba/F3 carrying
the native Bcr-Abl (Figure 1C). Furthermore, 1 μM of
Imatinib and Dasatinib failed to significantly inhibit
Ba/F3 cells carrying the T315I mutation (Figure 1D).
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Figure 1 Cooperation between GNF-2 and suboptimal concentration of Imatinib and Dasatinib in inhibiting proliferation of Bcr-Abl
transfected Ba/F3 cells. Ba/F3 cells, transfected with native p185 Bcr-Abl (A,C) and T315I mutated form (B,D) were treated with increasing
GNF-2 concentrations and with Imatinib at 0.2 μM (A) and 1 μM (B), or with dasatinib at 2 nM (A) and 1 μM (B). In (C) and (D) percentage of
viable Ba/F3 p185 Bcr-Abl (C) and Ba/F3 p185 Bcr-Abl T315I (D) cells treated with suboptimal concentration of Imatinib and Dasatinib for 72 h as
described in Materials and Methods. IC50 values +/− SD were calculated and blotted. Data are of representative experiment. Experiment was
repeated 3 times with similar outcomes. P-values; * p<0.05, ** p<0.005.
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2 from 0.65 to 0.12 and 0.1 μM, respectively, when cells
were treated for 72 h (Figure 1A). In addition, in Ba/F3
transfected with p185 Bcr-Abl T315I mutation, which
are refractory to Imatinib, Dasatinib, and GNF-2, pres-
ence of Imatinib and Dasatinib at 1 μM reduced the
IC50 of GNF-2 from 20 to 18 and 10 μM, respectively
(Figure 1B).
Interestingly, no cooperation was observed in inhibit-
ing the parental Ba/F3 cells by GNF-2 and AKIs
(Additional file 1: Figure S1 and S2).
Cooperation between GNF-2 and Abl Kinase Inhibitors
(AKIs) in inhibiting clonigenicity of BaF3/p185 Bcr-Abl
T315I cells
Anchorage-independent growth of cells is a typical char-
acteristic of the tumorigenicity of cancer cells in vitro
[9]. Thus, we tested the ability of Abl kinase inhibitors
(AKIs) to affect clonigenicity of Ba/F3 p185 Bcr-Abl
T315I in the presence of GNF-2.
Data presented in Figure 2 illustrated that GNF-2 was
active in substantially inhibiting clonigenicity of Ba/F3
p185 Bcr-Abl T315I at 100 μM (Figure 2A-2C). The cal-
culated IC50 was 25 μM (Figure 2D). As expected, cloni-
genicity of Ba/F3 p185 Bcr-Abl T315I was not affected
by all AKIs used at 100 nM or 1000 nM (Figure 2A-2C).
Addition of AKIs at 10 nM with various concentration
of GNF-2 did not sensitize Ba/F3 p185 Bcr-Abl T315Icells to GNF-2-dependent clonigenicity inhibition (data
not shown). However, presence of AKIs at 100 nM
showed a marginal cooperation between GNF-2 and
Imatinib and Nilotinib (Figure 2A-2B) and a greater co-
operation with Dasatinib (Figure 2C). The IC50 of GNF-2
was reduced from 25 μM to 14.8 μM, 16.5 μM and
13 μM when Imatinib, Nilotinib and Dasatinib at 100nM
were added, respectively (Figure 2D). When AKIs at
1 μM were used, we observed a more noticeable co-
operation with GNF-2. Presence of Imatinib (Figure 2A),
Nilotinib (Figure 2B) and Dasatinib (Figure 2C) reduced
the IC50 of GNF-2 to 10.5, 13, and 3.3 μM, respectively
(Figure 2D). Interestingly, Dasatinib was the most ef-
ficient AKI in cooperation with GNF-2 in inhibiting clo-
nigenicity of Ba/F3 cells containing the T315I mutated
Bcr-Abl.
Interestingly, no cooperation was observed in inhib-
iting the clonigenicity of the parental Ba/F3 cells by
GNF-2 and AKIs (Additional file 1: Figure S3).
Cooperation between GNF-2 and Abl Kinase Inhibitors
(AKIs) in inhibiting auto-phosphorylation of Bcr-Abl
Next, we tested whether the cooperation between GNF-2
and AKIs in proliferation and clonigenicity inhibition of
Bcr-Abl transfected Ba/F3 cells is mediated by interfering
with Bcr-Abl activity. Results presented in Figure 3 de-
monstrated, as expected, that GNF-2 is active in inhibiting
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Figure 2 (See legend on next page.)
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Figure 2 Cooperation between GNF-2 and AKIs in clonigenicity inhibition of Ba/F3 p185 Bcr-Abl T315I cells. Clonigenicity assay was
performed as described in Materials and Methods. Ba/F3 transfected cells were treated with GNF-2 at 5, 25 and 100 μM, in the presence of
0.1 μM and 1 μM of Imatinib (A), Nilotinib (B) and Dasatinib (C). IC50 values +/− SD were calculated and listed (D).
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and 0.01 μMNilotinib was used and resulted in marginally
reducing the amount of pBcr-Abl compared to control
samples (Figure 3A). However, a significant cooperation
was seen using Dasatinib (0.001 and 0.002 μM) (Figure 3B).
Levels of pBcr-Abl were partially reduced (50%) when
50 μM of GNF-2 were used (Figure 3B). However, presence
of 0.001 μM and 0.002 μM of Dasatinib inhibited com-
pletely pBcr-Abl levels (Figure 3B). Levels of pSTAT5α were
also marginally reduced when GNF-2 was applied in theA
B
C
Figure 3 Cooperation between GNF-2 and AKIs in inhibition phospho
Ph + cells carrying native Bcr-Abl (A and B), T315I mutated Bcr-Abl (C) and
various concentrations of GNF-2 in the presence of AKIs, as indicated in ea
were measured by immuno-blotting. The α-tubulin protein was used as loa
α-tubulin are shown.presence of Imatinib, Nilotinib (Figure 3A) and significantly
reduced in the presence of Dasatinib (Figure 3B).
Cooperation between GNF-2 and Abl Kinase Inhibitors
(AKIs) in inhibiting auto-phosphorylation of the mutated
T315I Bcr-Abl
Possible cooperation between GNF-2 and AKIs in mod-
ulating the phosphorylation of Bcr-Abl T315I protein
was also tested using cell-based auto-phosphorylation as-
say. Results presented in Figure 3C showed that GNF-2D
E
rylation of Bcr-Abl and STAT5α. Ba/F3, a laboratory model of
SupB15, a patient derived Ph+ ALL cell line (D-E) were treated with
ch figure. Phosphorylation levels of Bcr-Abl, c-Abl (D-E) and STAT5α
ding control. Relative values of pBcr-Abl, pAbl and pSTAT5α relative to
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p185 Bcr-Abl auto-phosphorylation nor with STAT5α
phosphorylation in Ba/F3 cells carrying the mutated
T315I form of Bcr-Abl (Figure 3C). Presence of AKIs
only marginally enhanced GNF-2 activity in affecting
Bcr-Abl auto-phosphorylation and STAT5α phosphoryl-
ation (Figure 3C).
Cooperation between GNF-2 and Abl Kinase Inhibitors
(AKIs) in inhibiting Bcr-Abl auto-phosphorylation in
patient derived SupB15 cell lines
Sub-optimal concentrations of AKIs were also used to
monitor cooperation with GNF-2 in SupB15, a patient
derived Ph+ ALL cell line. Data presented in Figure 3D
showed that GNF-2 at 0.5 μM is partially active in inhi-
biting Bcr-Abl auto-phosphorylation and STAT5α phos-
phorylation. Presence of Sub-optimal concentrations of
Nilotinib (5 nM) demonstrated good cooperation in
inhibiting Bcr-Abl auto-phosphorylation. Interestingly, we
noticed greater activity on Bcr-Abl compared to endogen-
ous c-Abl when Imatinib was used alongside GNF-2
(Figure 3D). Furthermore, cooperation was more pro-
found in inhibiting STAT5α phosphorylation (Figure 3D)
as evident in the combination of Imatinib and GNF-2.
Cooperation was also evident in the presence of low
Dasatinib concentration (0.2 nM) and this concentration
was sufficient to augment GNF-2 activity and to cause a
significant inhibition of Bcr-Abl auto-phosphorylation and
STAT5α phosphorylation when combined with 0.5 μM
of GNF-2 (Figure 3E). Presence of 0.2 nM Dasatinib
alongside of 0.5 μM GNF-2 reduced the relative pBcr-Figure 4 Effect of GNF-2 and AKIs on pBcr-Abl, pSTAT5α and pJAK2 i
carrying p185 Bcr-Abl T315I were exposed to IL-3 (10 ng/ml) and GNF2 (10
Nilotinib (0.1 μM) and Dasatinib (0.1 μM) and levels of Bcr-Abl, pBcr-Abl, pJ
previously described. Relative values of pBcr-Abl, pJAK2 and pSTAT5α relatiAbl, pAbl and pSTAT5α by 4.1, 1 and 24 fold, respect-
ively (Figure 3E).
Results in Figure 3 demonstrated that Abl proteins,
endogenous c-Abl and the chimeric Bcr-Abl, showed
different degrees of sensitivity to GNF-2 alone, and in
combinations with AKIs. GNF-2 alone, or with AKIs,
exhibited good inhibitory activity on Bcr-Abl auto-
phosphorylation, and only a marginal inhibition of the
endogenous c-Abl auto-phosphorylation (Figure 3A-3E).
Our data are consistent with observation made by Choi
et al., 2009 showing that GNF-2 inhibits the kinase activ-
ity of non-myristoylated c-Abl (Bcr-Abl) more potently
than that of myristoylated c-Abl (endogenous Abl) [10].
Cooperation between GNF-2 and Abl Kinase Inhibitors
(AKIs) in inhibiting JAK2 activity
Our data showed that cooperation of GNF-2 and Abl
kinase inhibitors (AKIs) on Ba/F3 p185 Bcr-Abl exhib-
ited a more profound activity on STAT5α phosphoryl-
ation than Abl auto-phosphorylation (Figure 3A-3E).
STAT5α phosphorylation is regulated by Bcr-Abl and
JAK2, thus we investigated the effect of GNF-2, in com-
bination with AKIs, on JAK2 activity.
The Ba/F3 Bcr-Abl T315I cells were treated with IL-3
and GNF-2/AKIs, and levels of pJAK2 and pSTAT5α
were monitored. Results presented in Figure 4 demon-
strated that levels of pJAK2 significantly increased in the
presence of IL-3. Treatment of Ba/F3 Bcr-Abl T315I cells
with GNF-2 caused a significant inhibition of pJAK2 at
the higher concentration used (50 μM). Presence of AKIs
augmented the inhibition of pJAK2 arguing that GNF-2
and AKIs cooperated in mediating inhibition of pJAK2.n Ba/F3p185 Bcr-Abl T315I exposed to IL-3 (10 ng/ml). Ba/F3 cells
μM and 50 μM) alone or in combination with Imatinib (1 μM),
AK2, pSTAT5α and α-tubulin were determined by immune-blotting as
ve to α-tubulin are shown.
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constitutively high and were further increased in the
presence of IL-3, while presence of GNF-2 or GNF-2/AKI
reduced pSTA5α to the levels obtained in the absence of
IL-3, arguing that STAT5α phosphorylation is mediated
mainly by Bcr-Abl and is less dependent on JAK2 activa-
tion, and suggesting that GNF-2 and AKIs are not direct
inhibitors of STAT5α.
Cooperation between GNF-2 and AKIs in inhibition
proliferation of Ba/F3 cells transfected with activated
JAK2 (JAK2 V617F) was also monitored. Data presented
in Figure 5 showed that Imatinib and Nilotinib at 1 μM
exhibited no inhibition of Ba/F3 JAK2 V617F prolifera-
tion (Figure 5B). In addition, GNF-2 inhibited prolifera-
tion of Ba/F3 JAK2 V617F with IC50 of 22 μM (Figure 5A).
Presence of 1 μM of Imatinib and Nilotinib reduced the
IC50 to 6.5 μM and 3 μM, respectively (Figure 5A). Pro-
liferation of Ba/F3 JAK2 V617F was significantly inhib-
ited by 1 μM Dasatinib (data not shown). Thus, we used
sub-optimal concentration of Dasatinib, 10 nM and 20 nM,
to assess potential cooperation with GNF-2 (Figure 5B).
Presence of Dasatinib at 10 nM or 20nM with GNF-2
inhibited proliferation of Ba/F3 JAK2 V617F with IC50 of
2.25 μM and 1.5 μM, respectively (Figure 5A).
Next, we evaluated whether the GNF-2/AKIs cooper-
ation also affects clonigenicity of Ba/F3 carrying the
JAK2 V617F mutation. Data presented in Figure 5C-E
showed that Imatinib, Nilotinib, and GNF-2 exhibited a
minimal effect on clonigenicity of Ba/F3 JAK2 V617F
cells. In contrast, AG490 (10 μM), a JAK2 inhibitor, sig-
nificantly inhibited the clonigenicity of Ba/F3 JAK2
V617F cells (Figure 3C-3E). The IC50 of GNF-2 was
22.5 μM, and presence of 1 μM of either Imatinib or
Nilotinib with GNF-2 significantly reduced the IC50 to
15.5 and 8 μM, respectively (Figure 5C and 5D). Al-
though 1 μM of Dasatinib was active in inhibiting the
clonigenicity of Ba/F3 JAK2 V617F cells (data not
shown), we found that concentrations below 30 nM have
a marginal effect on clonigenicity of the above cells (data
not shown). Thus, we tested potential cooperation be-
tween GNF-2 and 30 nM Dasatinib. Results present in
Figure 5E demonstrated a significant cooperation be-
tween Dasatinib and GNF-2 leading to the reduction of
IC50 from 22.5 μM to 2.5 μM.
Discussion and conclusion
Previously, the Abl allosteric inhibitor, GNF-2, was
shown to cooperate with Imatinib and Nilotinib in inhi-
biting Bcr-Abl [5]. Furthermore, GNF-2 was also re-
ported to cooperate with oligomerization inhibitors in
inhibiting Bcr-Abl, as well as in overcoming T315I re-
sistance [11]. Our results corporate the reported data
showing a cooperation between Abl allosteric inhibitor,
GNF-2, and Abl ATP competitors (Imatinib and Nilotinib),in inhibiting the proliferation of Ba/F3 cells carrying the
native or the T315I mutated Bcr-Abl. However, no co-
operation was observed between GNF-2 and AKIs in
controlling the proliferation and clonigenicity of the par-
ental Ba/F3 cells (Additional file 1). In this report we
also demonstrated that Dasatinib, an Abl/Src dual in-
hibitor, is capable of cooperating with GNF-2 in inhibit-
ing the proliferation of Ba/F3 cells carrying the native or
the T315I mutated Bcr-Abl. In fact, our data showed
that the cooperation with Dasatinib was more potent
than the one observed with Imatinib or Nilotinib. Fur-
thermore, cooperation between GNF-2 and AKIs was
also evident in inhibiting clonigenicity of Ba/F3 cells car-
rying the T315I mutation of Bcr-Abl. Presence of 1 μM
of the AKIs reduced the IC50 of GNF-2 from 25 μM to
10.5 μM, 13 μM, and 3.5 μM when Imatinib, Nilotinib
and Dasatinib were used, respectively. Although we did
not closely investigate the nature of the cooperation be-
tween AKIs and GNF-2 in the current study, it seems
that GNF-2 and Dasatinib cooperated in a synergistic
manner which is consistent with Mian et al., 2012 find-
ing who demonstrated a synergistic relation between
GNF-2 and Dasatinib [12].
Weisberg et al., 2010 showed that HG-7-85-01, ATP
competitor, is capable of inhibiting the Bcr-Abl-T315I
gatekeeper mutant. Furthermore, HG-7-85-01 was found
to have additive effect in in-vitro and in vivo models
in a Bcr-Abl-dependent fashion [1]. Our study utilized
GNF-2, and other AKIs that are not active in inhibit-
ing the T315I mutation, resulting in the inhibition of
proliferation and clonigenicity of the T315I cells via a
mechanism that is not dependent on Bcr-Abl, but ra-
ther on an alternative or downstream pathways.
Next, we explored the molecular mechanism respon-
sible for the observed cooperation. Initially, we moni-
tored the cooperation between GNF-2 and suboptimal
concentration of AKIs in inhibiting the native Bcr-Abl
auto-phosphorylation. Our results, presented in Figure 3,
showed a moderate cooperation in inhibiting the phos-
phorylation of native Bcr-Abl and STAT5α. Our data are
in agreement with data generated using flow cytometry
analysis illustrating that GNF-5, a GNF-2 analog, coop-
erated with Nilotinib to inhibit STAT5α phosphorylation
[5]. In contrast, only minimal cooperation was seen when
Ba/F3 cells carrying the T315I Bcr-Abl was used. These
results illustrated that the cooperative inhibition of Ba/F3
cells' proliferation and clonigenicity is not mediated by
the Bcr-Abl protein, and that probably the two kinase
inhibitors target downstream or alternative signaling
pathways that control the growth of these cells.
Results shown in Figures 4 and 5 illustrated that JAK2
is also targeted by GNF-2, however, with reduced po-
tency, consistent with the presence of a myristate bind-





Figure 5 Cooperation between GNF-2 and AKIs in inhibiting proliferation and clonigenicity of Ba/F3 JAK2 V617F cells. (A). Effect of
GNF-2 and sub-optimal concentrations of AKIs on the observed IC50s using Ba/F3 JAK2 V617F cells. (B). Percentage of viable cells (+/− SD) treated
for 72 h with AKIs at the indicated concentrations. Effect of GNF-2 with Imatinib (C), Nilotinib (D) and Dasatinib (E) on the anchorage-
independent growth of Ba/F3 JAK2 V617F cells was evaluated using a colony forming assay, and the concentrations inhibiting clonigenicity by
50% (IC50) were calculated. P-values * p<0.05, ** p<0.005.
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hibitory effect exerted by GNF-2. Interestingly, combin-
ation of GNF-2 and Dasatinib was the most efficient
combination in inhibiting JAK2 phosphorylation.
Our data are also consistent with findings made by
Nelson et al., 2011 showing that inhibitors of alternate
pathways, such as STAT5α inhibitors, might be utilized
as an effective therapy for Ph+ leukemia carrying native
and T315I mutated Bcr-Abl [13]. The enhanced activity
of the combination of GNF-2 with Dasatinib, a dual src/
Abl kinase inhibitor, might be due to the inhibitory ac-
tivity of Dasatinib on Src kinase which is involved in
STAT5α phosphorylation [14].
In conclusion, our data provide evidence for cooper-
ation between GNF-2 and AKIs in inhibiting prolif-
eration and clonigenicity of Ba/F3 cells carrying T315I
mutated Bcr-Abl construct. In our experimental system
we used a laboratory model of p190 Bcr–Abl, a variant
commonly found in acute lymphocytic leukemia (ALL)
that typically responds only transiently to AKIs therapy,
arguing that ALL patients may benefits from such com-
bination. Cooperation between GNF-2 and AKIs was not
mediated by Bcr-Abl protein inhibition, since the phos-
phorylation levels of Bcr-Abl and STA5α were not
affected in Ba/F3 harboring T315I mutated Bcr-Abl. In
summary, we showed that drug combination of allosteric
inhibitors and AKIs, Dasatinib in particular, allows over-
coming resistance in Ph+ leukemia cells, including cells
harboring the T315I mutation.Additional file
Additional file 1: Effect of GNF-2 and Abl kinase Inhibitors (AKIs) on
the proliferation and clonigenicity of Ba/F3 cells. Figure S1: Effect of
Imatinib and Dasatinib on the proliferation of Ba/F3 (Blue) and Ba/F3
p185 Bcr-Abl (Red) cells. The cells supplemented with 10 ng/ml of IL-3,
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